Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer grouped in the class of keratinocyte cancer, or non-melanoma skin cancer. It is derived from cells within the epidermis that make keratin, the protein which makes up skin, hair, and nails. Cutaneous squamous cell carcinoma (cSCC) is an invasive disease, referring to cancer cells that have grown beyond the epidermis. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma.
Market Dynamics
Rising incidence of cutaneous squamous cell carcinoma (cSCC) is expected to drive cutaneous squamous-cell carcinoma treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that squamous cell carcinoma is the second most common form of skin cancer in the U.S followed by basal cell carcinoma. It also reports that over one million squamous cell carcinoma cases are diagnosed in the U.S. each year.
However, lack of standardization in the guidelines for cutaneous squamous cell carcinoma (cSCC) creates a challenge for physicians to execute the treatment, and this is expected to hinder the market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that physician's challenge lies in properly assessing a patient's risk for aggressive disease based on tumor or host characteristics.
Key features of the study:
- This report provides in-depth analysis of the global cutaneous squamous-cell carcinoma treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cutaneous squamous-cell carcinoma treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global cutaneous squamous-cell carcinoma treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cutaneous squamous-cell carcinoma treatment market.
Detailed Segmentation:
- Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment:
- Surgical
- Moh’s Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
- Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Application:
-
- Hospitals
- Cancer Institutes
- Ambulatory Surgical Centers
- Others
- Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Region:
- North America
- By Treatment:
- Surgical
- Moh’s Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
- By Application:
- Hospitals
- Cancer Institutes
- Ambulatory Surgical Centers
- Others
- By Country:
- Latin America
- By Treatment:
- Surgical
- Moh’s Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
- By Application:
- Hospitals
- Cancer Institutes
- Ambulatory Surgical Centers
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Treatment:
- Surgical
- Moh’s Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
- By Application:
- Hospitals
- Cancer Institutes
- Ambulatory Surgical Centers
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Treatment:
- Surgical
- Moh’s Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
- By Application:
- Hospitals
- Cancer Institutes
- Ambulatory Surgical Centers
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Treatment:
- Surgical
- Moh’s Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
- By Application:
- Hospitals
- Cancer Institutes
- Ambulatory Surgical Centers
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Treatment:
- Surgical
- Moh’s Micrographic Surgery (MMS)
- Electrodessication or Curettage
- Non-surgical
- Chemotherapy
- Topical Immune Response Modifiers
- Radiotherapy
- Systemic Chemotherapy
- By Application:
- Hospitals
- Cancer Institutes
- Ambulatory Surgical Centers
- Others
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Eli Lilly and Company*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Sanofi S.A.
- Cadila Healthcare Limited.
- Cipla Limited
- Castle Biosciences
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Vidac Pharma
- LEO Pharma A/S
- Regeneron Pharmaceuticals, Inc.
- Merck Sharp & Dohme
- Amgen Inc.
“*” marked represents similar segmentation in other categories in the respective section.
